{"id":76690,"date":"2026-08-26T13:11:44","date_gmt":"2026-08-26T05:11:44","guid":{"rendered":"https:\/\/flcube.com\/?p=76690"},"modified":"2026-08-26T13:11:46","modified_gmt":"2026-08-26T05:11:46","slug":"nmpa-approves-novartis-pluvicto-plus-arpi-for-psma-positive-mhspc-in-china-advancing-radioligand-therapy-to-earlier-prostate-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76690","title":{"rendered":"NMPA Approves Novartis&#8217; Pluvicto Plus ARPI for PSMA\u2011Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Novartis (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/NVS:NYSE\">NYSE: NVS<\/a>)<\/strong> announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has approved the <strong>radioligand therapy (RLT) Pluvicto (lutetium [177Lu] vipivotide tetraxetan injection)<\/strong> in combination with an <strong>androgen receptor pathway inhibitor (ARPI)<\/strong> for the treatment of <strong>prostate\u2011specific membrane antigen (PSMA)\u2011positive metastatic hormone\u2011sensitive prostate cancer (mHSPC)<\/strong>. This approval marks a further advancement of <strong>Pluvicto&#8217;s<\/strong> clinical application in China, moving from metastatic castration\u2011resistant prostate cancer (mCRPC) into the earlier\u2011stage mHSPC setting.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>26 Aug 2026<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Pluvicto (lutetium [177Lu] vipivotide tetraxetan injection) + ARPI<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>PSMA\u2011positive metastatic hormone\u2011sensitive prostate cancer (mHSPC)<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>Advancement from mCRPC to earlier\u2011stage mHSPC in China<\/td><\/tr><tr><td><strong>Supporting Data<\/strong><\/td><td>Phase 3 PSMAddition study<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Pluvicto<\/strong> \u2013 a radioligand therapy (RLT) combining a PSMA\u2011targeting ligand with the beta\u2011emitting radioisotope lutetium\u2011177<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Binds PSMA\u2011expressing prostate cancer cells and delivers targeted radiation, inducing tumour cell death while sparing surrounding tissue<\/li>\n\n\n\n<li><strong>Combination Rationale:<\/strong> Pairing RLT with an <strong>ARPI<\/strong> in the hormone\u2011sensitive setting attacks the tumour through complementary mechanisms earlier in the disease course<\/li>\n\n\n\n<li><strong>Patient Selection:<\/strong> PSMA\u2011positive disease, enabling precision targeting of radioligand therapy<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-psmaddition-phase-3\" class=\"wp-block-heading\">Clinical Evidence \u2013 PSMAddition (Phase 3)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Outcome (Pluvicto + ARPI vs. Control)<\/th><\/tr><\/thead><tbody><tr><td><strong>Radiographic Progression\u2011Free Survival (rPFS)<\/strong><\/td><td>Significantly improved<\/td><\/tr><tr><td><strong>Relative Risk of Radiographic Progression or Death<\/strong><\/td><td><strong>33% reduction<\/strong> (HR 0.67; 95% CI 0.55\u20130.82)<\/td><\/tr><tr><td><strong>Subgroup Consistency<\/strong><\/td><td>rPFS benefit favoured the combination across all subgroups, regardless of baseline disease burden or de novo vs. recurrent mHSPC<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The pivotal Phase 3 <strong>PSMAddition<\/strong> study demonstrated that combination therapy with <strong>lutetium [177Lu] vipivotide tetraxetan<\/strong> significantly improved radiographic progression\u2011free survival compared to the control group, with subgroup analyses consistent with the overall population \u2014 reinforcing the breadth of benefit across the mHSPC patient landscape.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Earlier\u2011Line Expansion:<\/strong> Moving <strong>Pluvicto<\/strong> from mCRPC into mHSPC substantially enlarges the addressable patient population in China, where prostate cancer incidence continues to rise and is often diagnosed at advanced stages.<\/li>\n\n\n\n<li><strong>RLT Category Leadership:<\/strong> The approval consolidates <strong>Novartis&#8217;s<\/strong> position at the forefront of radioligand therapy and signals the maturation of China&#8217;s nuclear medicine infrastructure as a growth channel.<\/li>\n\n\n\n<li><strong>Competitive Dynamics:<\/strong> With a 33% reduction in progression risk and cross\u2011subgroup consistency, the Pluvicto + ARPI combination is positioned as a differentiated first\u2011line option against incumbent ARPI monotherapy standards in PSMA\u2011positive mHSPC.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical uptake, reimbursement, and commercial expectations for Pluvicto in China. Actual results may differ due to risks including market adoption, radioligand supply infrastructure, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novartis (NYSE: NVS) announced that the National Medical Products Administration (NMPA) has approved the radioligand&#8230;<\/p>\n","protected":false},"author":1,"featured_media":76691,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11,4908],"tags":[140,865,15],"class_list":["post-76690","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","category-pic","tag-novartis","tag-nyse-nvs","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NMPA Approves Novartis&#039; Pluvicto Plus ARPI for PSMA\u2011Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novartis (NYSE: NVS) announced that the National Medical Products Administration (NMPA) has approved the radioligand therapy (RLT) Pluvicto (lutetium [177Lu] vipivotide tetraxetan injection) in combination with an androgen receptor pathway inhibitor (ARPI) for the treatment of prostate\u2011specific membrane antigen (PSMA)\u2011positive metastatic hormone\u2011sensitive prostate cancer (mHSPC). This approval marks a further advancement of Pluvicto&#039;s clinical application in China, moving from metastatic castration\u2011resistant prostate cancer (mCRPC) into the earlier\u2011stage mHSPC setting.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76690\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NMPA Approves Novartis&#039; Pluvicto Plus ARPI for PSMA\u2011Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer\" \/>\n<meta property=\"og:description\" content=\"Novartis (NYSE: NVS) announced that the National Medical Products Administration (NMPA) has approved the radioligand therapy (RLT) Pluvicto (lutetium [177Lu] vipivotide tetraxetan injection) in combination with an androgen receptor pathway inhibitor (ARPI) for the treatment of prostate\u2011specific membrane antigen (PSMA)\u2011positive metastatic hormone\u2011sensitive prostate cancer (mHSPC). This approval marks a further advancement of Pluvicto&#039;s clinical application in China, moving from metastatic castration\u2011resistant prostate cancer (mCRPC) into the earlier\u2011stage mHSPC setting.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76690\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-26T05:11:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-26T05:11:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2609.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76690#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76690\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NMPA Approves Novartis&#8217; Pluvicto Plus ARPI for PSMA\u2011Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer\",\"datePublished\":\"2026-08-26T05:11:44+00:00\",\"dateModified\":\"2026-08-26T05:11:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76690\"},\"wordCount\":440,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76690#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2609.webp\",\"keywords\":[\"Novartis\",\"NYSE: NVS\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\",\"PIC\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76690#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76690\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76690\",\"name\":\"NMPA Approves Novartis' Pluvicto Plus ARPI for PSMA\u2011Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76690#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76690#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2609.webp\",\"datePublished\":\"2026-08-26T05:11:44+00:00\",\"dateModified\":\"2026-08-26T05:11:46+00:00\",\"description\":\"Novartis (NYSE: NVS) announced that the National Medical Products Administration (NMPA) has approved the radioligand therapy (RLT) Pluvicto (lutetium [177Lu] vipivotide tetraxetan injection) in combination with an androgen receptor pathway inhibitor (ARPI) for the treatment of prostate\u2011specific membrane antigen (PSMA)\u2011positive metastatic hormone\u2011sensitive prostate cancer (mHSPC). This approval marks a further advancement of Pluvicto's clinical application in China, moving from metastatic castration\u2011resistant prostate cancer (mCRPC) into the earlier\u2011stage mHSPC setting.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76690#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76690\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76690#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2609.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2609.webp\",\"width\":1080,\"height\":608,\"caption\":\"NMPA Approves Novartis' Pluvicto Plus ARPI for PSMA\u2011Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76690#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NMPA Approves Novartis&#8217; Pluvicto Plus ARPI for PSMA\u2011Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NMPA Approves Novartis' Pluvicto Plus ARPI for PSMA\u2011Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Novartis (NYSE: NVS) announced that the National Medical Products Administration (NMPA) has approved the radioligand therapy (RLT) Pluvicto (lutetium [177Lu] vipivotide tetraxetan injection) in combination with an androgen receptor pathway inhibitor (ARPI) for the treatment of prostate\u2011specific membrane antigen (PSMA)\u2011positive metastatic hormone\u2011sensitive prostate cancer (mHSPC). This approval marks a further advancement of Pluvicto's clinical application in China, moving from metastatic castration\u2011resistant prostate cancer (mCRPC) into the earlier\u2011stage mHSPC setting.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76690","og_locale":"en_US","og_type":"article","og_title":"NMPA Approves Novartis' Pluvicto Plus ARPI for PSMA\u2011Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer","og_description":"Novartis (NYSE: NVS) announced that the National Medical Products Administration (NMPA) has approved the radioligand therapy (RLT) Pluvicto (lutetium [177Lu] vipivotide tetraxetan injection) in combination with an androgen receptor pathway inhibitor (ARPI) for the treatment of prostate\u2011specific membrane antigen (PSMA)\u2011positive metastatic hormone\u2011sensitive prostate cancer (mHSPC). This approval marks a further advancement of Pluvicto's clinical application in China, moving from metastatic castration\u2011resistant prostate cancer (mCRPC) into the earlier\u2011stage mHSPC setting.","og_url":"https:\/\/flcube.com\/?p=76690","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-26T05:11:44+00:00","article_modified_time":"2026-08-26T05:11:46+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2609.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76690#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76690"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NMPA Approves Novartis&#8217; Pluvicto Plus ARPI for PSMA\u2011Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer","datePublished":"2026-08-26T05:11:44+00:00","dateModified":"2026-08-26T05:11:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76690"},"wordCount":440,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=76690#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2609.webp","keywords":["Novartis","NYSE: NVS","Product approvals"],"articleSection":["Company","Drug","PIC"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76690#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76690","url":"https:\/\/flcube.com\/?p=76690","name":"NMPA Approves Novartis' Pluvicto Plus ARPI for PSMA\u2011Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=76690#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=76690#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2609.webp","datePublished":"2026-08-26T05:11:44+00:00","dateModified":"2026-08-26T05:11:46+00:00","description":"Novartis (NYSE: NVS) announced that the National Medical Products Administration (NMPA) has approved the radioligand therapy (RLT) Pluvicto (lutetium [177Lu] vipivotide tetraxetan injection) in combination with an androgen receptor pathway inhibitor (ARPI) for the treatment of prostate\u2011specific membrane antigen (PSMA)\u2011positive metastatic hormone\u2011sensitive prostate cancer (mHSPC). This approval marks a further advancement of Pluvicto's clinical application in China, moving from metastatic castration\u2011resistant prostate cancer (mCRPC) into the earlier\u2011stage mHSPC setting.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76690#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76690"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=76690#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2609.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2609.webp","width":1080,"height":608,"caption":"NMPA Approves Novartis' Pluvicto Plus ARPI for PSMA\u2011Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76690#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NMPA Approves Novartis&#8217; Pluvicto Plus ARPI for PSMA\u2011Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2609.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76690"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76690\/revisions"}],"predecessor-version":[{"id":76692,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76690\/revisions\/76692"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/76691"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}